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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of any therapy or treatment used in the management of ENL.
B A C K G R O U N D
Description of the condition
Leprosy is a chronic infectious disease caused by the bacillus My-
cobacterium (M.) leprae. Leprosy bacilli are spread as tiny droplets
from the nose or mouth of infected and untreated individuals.
When the immune system fails to respond effectively, the disease
will develop. Often, the first sign of leprosy is a patch on the skin,
but damage to peripheral nerves may occur as well. Leprosy can
appear in various clinical forms, dependent on the response of
the immune system. Some people have only a few skin patches
and the number of bacilli is relatively small. This is classified as
paucibacillary (PB) leprosy. Other people have many skin patches
and a high number of bacilli in their body and are classified as
multibacillary (MB) leprosy (ILEP 2001; WHO 2006a). At the
beginning of 2006 the prevalence was about 220,000 worldwide.
The number of newly detected cases was approximately 296,000
during 2005 (WHO 2006b).
The body’s immune response to the leprosy bacilli may also cause
’so-called’ reactions. There are two types of reactions: type 1 re-
action or reversal reaction (RR) and type 2 reaction or erythema
nodosum leprosum (ENL). Type 1 or RR presents as acute in-
flammation in skin lesions and nerves. ENL presents as new, red,
painful and tender swellings in the skin, usually on the legs and
arms, and sometimes on the trunk. ENL varies in severity. When
the reaction is mild, only the skin is affected and there may be low-
grade fever.When the reaction is severe, the swellings are multiple
and may ulcerate, and other organs may be inflamed, such as the
nerves, eyes, joints, testes, and lymph nodes (ILEP 2002; WHO
2003). Most people with ENL have recurrent episodes which may
occur over a period of several years. Few people experience a single
acute episode of ENL (Nery 1998; Saunderson 2000; Pocaterra
2006).
ENL only occurs in people with MB leprosy, especially in those
classified as borderline lepromatous (BL) or lepromatous (LL) lep-
rosy. These people have a high number of bacilli in their body
which increases the risk of ENL. The percentage of people diag-
nosed with ENL seems to differ between countries and studies.
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For instance, a study fromEthiopia reported only 5%ENL among
people with MB leprosy, while a study from Brasil found an in-
cidence of 31% (Nery 1998; Saunderson 2000). ENL may occur
before the start of treatment, but develops most often within the
first three years after the start of multi drug therapy (MDT). After
completion of treatment, people may still have episodes of ENL
for several years. This depends mainly on the number of bacilli
remaining in the body after treatment (ILEP 2002; Naafs 2003a).
Causes
ENL is caused partly by immune complexes of M. leprae anti-
gen and antibody. These complexes circulate in the blood and
may precipitate in tissue, particularly on the wall of small blood
vessels, causing acute inflammation (vasculitis) and release of tis-
sue-damaging enzymes. In addition, the immune system activates
cells (macrophages and T cells) that attack and kill the bacilli
(Lockwood 1996; Naafs 2003b). Studies have shown that some
people have a higher risk of getting ENL, such as people with
lepromatous leprosy or with many bacilli, and people aged 40 or
younger (Manandhar 1999; Saunderson 2000; Kumar 2004).
Impact
People who have ENL usually feel ill (general malaise, fever) and
many organs may be affected. ENL is often a recurrent or chronic
condition and requires treatment for a long period (Nery 1998;
Saunderson 2000; Pocaterra 2006). More than most other dis-
eases, leprosy has a very negative image. Having visible signs of
leprosy or side-effects from treatment can trigger discrimination
and stigmatization (Heijnders 2004; Rafferty 2005). The psycho-
logical impact of a chronic and stigmatizing condition may be
profound.
Description of the intervention
Most therapies for ENL aim to control the acute inflammation,
relieving the pain and preventing further damage or new episodes.
Several treatments are available for ENL.
The conventional treatment for mild ENL is rest and anti-inflam-
matory medication. Aspirin is the most commonly used anti-in-
flammatory, but indomethacin, chloroquine and colchicine have
been tested as well. There is not much evidence that these drugs
are more beneficial than aspirin (ILEP 1996; Lockwood 1996).
For severe ENL, prednisolone, the most widely available corticos-
teroid, and clofazimine are most commonly used. Prednisolone
usually acts rapidly in controlling ENL. The starting dose should
be the lowest possible to control ENL and gradually reduced as
soon as possible. The schedule for reducing prednisolone depends
on the course of the disease. ENL is often recurrent or chronic
and requires high-dose and prolonged courses of prednisolone for
disease control. This increases the risk of adverse events, such as
hypertension or diabetes, and steroid dependency (ILEP 1996;
Lockwood 1996; ILEP 2002).
Leprosy infection can be effectively treated with a combination
of antibiotics. Multidrug therapy (MDT) with the antibiotics ri-
fampicin, dapsone and clofazimine was introduced in the 1980s
and is provided free by the World Health Organization (WHO)
(ILEP 2001; WHO 2006a). Since the introduction of MDT, the
number of people affected by leprosy has decreased substantially.
Before the introduction of MDT, as many as half of those with
MB leprosy developed ENL (Lockwood 1996; Saunderson 2000).
Since MDT has been provided the number of new people with
ENL has decreased substantially. This reduction is probably due
to earlier diagnosis and treatment and to the effect of clofazimine,
one of the drugs used in MDT for MB leprosy (Pocaterra 2006).
Clofazimine is a useful drug when corticosteroids are contraindi-
cated or need to be reduced. Treatment with clofazimine usually
needs more time and higher doses, because it is less effective than
corticosteroids. The dose of clofazimine needed to control ENL is
higher than the dose used in MDT. Disadvantages of continuous
high doses of clofazimine are gastrointestinal symptoms (e.g. diar-
rhoea) andbrowndiscolorationof the skin (ILEP 1996; Lockwood
1996; WHO 2003).
Another highly effective, but controversial, drug in the manage-
ment of ENL is thalidomide. The major problem with thalido-
mide is that it may cause serious birth defects when taken in early
pregnancy. Therefore, the WHO does not support the use of this
drug (ILEP 1996; WHO 2003).
Other therapies have been tested, such as cyclosporin A, pentox-
ifylline, oral zinc, and Mycobacterium w vaccination (Uyemura
1986; Zaheer 1993; Mahajan 1994; Nery 2000). New therapies
for other immune-mediated conditions seem promising. Exam-
ples are TNF-α antibody treatment, intravenous immunoglobu-
lin, and tenidap (Lockwood 1996). It is plausible that these thera-
pies may be effective for controlling ENL, but evidence from ran-
domized controlled trials is very limited.
Why it is important to do this review
ENL is a serious immunological complicationof leprosy. The com-
plex mechanisms underlying ENL are not fully understood yet
which makes treatment difficult. Corticosteroids and clofazimine
are the drugs of choice for ENL, but both have drawbacks and the
optimal regimen has not been established. Alternative therapies
have been tested, but it is unclear if they are beneficial, or which
one is preferable. The role of newer treatments, such as TNF-α
antibody treatment, intravenous immunoglobulin, and tenidap,
is not known.
O B J E C T I V E S
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To assess the effects of any therapy or treatment used in the man-
agement of ENL.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of any design.
Types of participants
Anyone affected by leprosy with ENL, confirmed by appropriate
clinical features. The definition of ENL is: ’an inflammatory con-
dition involving the humoral immune system, in which people
develop crops of tender erythematous subcutaneous skin lesions’.
There may be accompanying neuritis, iritis (inflammation of the
iris), arthritis, orchitis (inflammation of the testicles), dactylitis
(inflammation of the fingers and toes), lymphadenopathy, oedema
and fever. The skin signs are obligatory; the nerve and general signs
optional (Smith 2002; Van Brakel 2005).
Types of interventions
Any therapy for ENL, including:
(1) Systemic corticosteroids
• Oral therapies: prednisolone
• Intravenous therapies: betamethasone, methylprednisolone
(2) Systemic non-steroidal immunomodulatory therapies
• Immunosuppressive therapies: thalidomide, cyclosporin A,
pentoxifylline
• Antibacterial therapies: clofazimine
• Anti-inflammatory therapies: aspirin, chloroquine,
colchicine, indomethacin
(3) Diverse therapies
• Oral zinc
• Mycobacterium w vaccine
The comparators will be no treatment, placebo, usual care (e.g.
systemic corticosteroid with or without pentoxifylline) or another
listed therapy. We shall include trials which compare different
dosages of the same therapy or different routes of administration
(e.g. intravenous versus oral systemic corticosteroids).
Types of outcome measures
Primary outcomes
(i) The proportion of participants achieving remission of
skin lesions
Remission is defined as the absence of new tender erythematous
subcutaneous skin lesions at completion of the ENL therapy, as
assessed by a clinician.
Secondary outcomes
(ii) The proportion of participants achieving remission of
other inflammations
Remission is defined as the disappearance of other inflammations
associated with ENL (e.g. iritis, arthritis) at completion of the
ENL therapy, as assessed by a clinician.
(iii) Investigator-assessed change in ENL severity
The change in ENL severity, compared to baseline, using a grading
scale as used in each of the studies.
(iv) Time to next clinical episode of ENL
Time to next clinical episode of ENL is defined as the time between
the last dose of ENL treatment and appearance of new signs of
ENL reaction.
(v) Changes in quality of life
As assessed using a recognised instrument (generic, dermatology
specific, disease specific, or patient-generated index).
Adverse outcomes
We are looking at a very wide range of interventions and can-
not pre-specify which are the most important / common adverse
events. Therefore we shall document the incidence and severity of
all recorded local and systemic adverse events, at any time point,
in all the included studies.
Economic data
Data relating to costs will not be reported, but we will address cost
implications in the discussion.
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Timing of outcome assessment
Data that has been recorded for less than four weeks from the start
of treatment will be considered to reflect short-term benefit and
will be analysed separately from data that was recorded for longer
than three months from the start of treatment, which we consider
to reflect the minimum time period to capture any longer-term
benefit. The short-term assessment (one to four weeks) will be
considered the primary endpoint, because the definite treatment
effects should be visible within the first weeks. The long-term as-
sessment (three to six months) will be used as a secondary end-
point.
Search methods for identification of studies
Electronic searches
We shall search for relevant published trials in:
• the Cochrane Skin Group Specialised Register, and the
Cochrane Central Register of Controlled Trials in The Cochrane
Library (last update);
• MEDLINE (from 2003) and EMBASE (from 2005),
• AMED (Allied and Complementary Medicine, from 1985),
CINAHL (from 1980), and LILACS (Latin American and
Caribbean Health Science Information database, from 1982).
We shall search for ongoing trials in:
• the metaRegister of Controlled Trials (www.controlled-
trials.com);
• the ongoing trials website of the Cochrane Skin Group
(www.nottingham.ac.uk/csg/about/ongoingtrial).
(i) Search strategy to locate RCTs
Search terms 1-29, as given in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2005), Appendix 5b.2.
(ii) Strategy to locate erythema nodosum leprosum (ENL)
30. leprosy.mp. or exp LEPROSY/
31. type 2 reaction.mp.
32. lepra reaction.mp.
33. ENL.mp.
34. *Erythema Nodosum/
35. LEPROSY, BORDERLINE/
36. LEPROSY, LEPROMATOUS/
37. 30 and 31
38. 30 and 33
39. 32 or 34 or 35 or 36 or 37 or 38
40. 29 and 39
The results of searches (i) and (ii) will be combined with the
Boolean operator ’AND’.
This is a draft search strategy and will be adapted to include addi-
tional search terms where necessary and will be modified for the
other databases listed.
Searching other resources
Reference lists
We shall scan the bibliographies of the included studies and reviews
for possible references to RCTs.
Unpublished literature
We shall attempt to find unpublished or ongoing trials via corre-
spondence with trial authors of included and excluded trials less
than 15 years old.
Handsearching
Conference proceedings from relevant leprosy meetings will be
scanned for RCTs and, where possible, the authors will be con-
tacted for further information.
Adverse effects
We shall not do a separate search for adverse events, however, we
shall search within the included studies.
Language restrictions
No language restrictions will be imposed when searching for pub-
lications, and translations will be sought where necessary.
Data collection and analysis
Selection of studies
Two authors (NvV and JHR) will check the titles and abstracts
identified from the searches. If it is clear that the study does not
refer to a randomised controlled trial of an ENL intervention, we
shall exclude it. The same two authors will independently assess
the full text version of each remaining study to determine whether
it meets the pre-defined selection criteria. Any differences of opin-
ion will be resolved through discussion within the review team.
We shall list the excluded studies and reasons for exclusion in the
’Characteristics of excluded studies’ table. These will not be dis-
cussed further.
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Data extraction and management
Two authors (NvV and JHR) will independently extract the data
using a specially designed data extraction form. A third teammem-
ber (WvB) will resolve any differences in opinion. Two authors
(NvV and JHR) will independently check and enter the data into
RevMan.
For the participant’s and investigator’s global assessments of im-
provement, the authors will translate reported changes in ENL
severity into the proportion of participants with improvement
greater than minimal. By minimal we mean anything greater than
the first category of improvement on a Likert scale, or greater than
50% improvement from baseline on a continuous scale. For the
purpose of calculating clinical efficacy, we shall regard categories
relating to greater than minimal improvement as a treatment suc-
cess.
All other outcomes will be expressed as the actual or percentage
change from baseline.
Assessment of risk of bias in included studies
The quality assessment will include an evaluation of the following
components for each included study, since there is some evidence
that these are associated with biased estimates of treatment effect
(Juni 2001):
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it will be considered
’adequate’ if the assignment could not be foreseen;
(c) who was blinded and not blinded (participants, clinicians, out-
come assessors) if this is appropriate;
(d) how many participants were lost to follow up in each arm, and
whether reasons for losses were adequately reported;
(e) whether all participants were analysed in the groups to which
they were originally randomised (intention to treat principle).
In addition we shall report on:
(f ) the degree of certainty that the participants have ENL;
(g) the baseline assessment of the participants for age, sex, duration
and severity of ENL;
(h) whether outcome measures were described.
We shall describe the quality of each study, based on these compo-
nents, in the section on Methodological quality of included stud-
ies. We shall also record this information in a ’Table of quality
criteria’.
Measures of treatment effect
We shall express the results as risk ratio (RR) and 95% confi-
dence intervals (CI) for dichotomous outcomes, and differences in
means (MD) and 95% CI for continuous outcomes. We shall use
a standardised mean difference to combine continuous outcome
measures, since they are likely to be from different scales across
the studies, such as quality of life. We shall express the result as
’number needed to treat’ where appropriate, for a range of plausi-
ble control event rates. For time to event outcomes, the log hazard
ratio and 95% confidence interval will be summarised.
Unit of analysis issues
Where there are multiple intervention groups within a trial, we
shall make pairwise comparisons of similar ENL interventions or
ENL active components versus no treatment, placebo, or another
ENL intervention. We shall analyse cross-over trials using data
from the first phase only and pooled, where possible, with parallel
design studies. We shall analyse internally controlled trials using
appropriate techniques for paired designs and these studies will
not be pooled with studies of other designs. We shall exclude non-
randomised controlled studies from the analyses but these may be
commented on in the discussion.
Dealing with missing data
If participant drop out leads to missing data, we shall conduct an
intention-to-treat analysis. We shall contact trial authors or spon-
sors of studies less than 15 years old to provide missing statistics
such as standard deviations. For dichotomous outcomes, we shall
regard participants with missing outcome data as treatment fail-
ures and include these in the analysis. For continuous outcomes,
we shall carry forward the last recorded value for participants with
missing outcome data.
Data synthesis
For studies with a similar type of ENL intervention or a similar
active component, we shall perform a meta-analysis to calculate
a weighted treatment effect across trials, using a random-effects
model.Where it is not possible to perform ameta-analysis we shall
summarise the data for each trial.
Subgroup analysis and investigation of heterogeneity
We shall assess statistical heterogeneity using I2. If substantial het-
erogeneity (I2>50%) exists between studies for the primary out-
come, we shall explore the reasons for heterogeneity; such as dis-
ease severity, dosage and duration of treatment. We shall perform
further subgroup analysis where adequate information is given.
The groups will be different severity of ENL (mild or severe), and
different durationof ENL (single acute,multiple acute or chronic).
Sensitivity analysis
We plan to conduct sensitivity analyses to examine the effects of
excluding poor quality studies, defined as those with a moderate
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or high risk of bias as described in the Cochrane Handbook of
Systematic Reviews of Interventions (Higgins 2005).
Adverse outcomes
We shall describe the information qualitatively.
Other
Where there is uncertainty, we shall contact the trial authors for
clarification. A consumer is part of the review team to ensure the
relevance and readability of the final review.
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